| Source:
NICOX
| For information | ||
| Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021 | ||
|
June 23, 2021 Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, announced that results from the Dolomites Phase 2 clinical trial on NCX 470 in patients with open-angle glaucoma or ocular hypertension will be presented by Dr. David Wirta, Medical Director, Eye Research Foundation (Newport Beach, CA, USA), at the World Glaucoma E-Congress 2021 being held from June 30 – July 3, 2021. Dr. Wirta is one of the clinical investigators in the Dolomites trial. Dr. Wirta’s presentation will be available from June 30, 2021 on the website of the World Glaucoma E-Congress via a link dedicated to the E-posters. Nicox’s lead clinical development product candidate, NCX 470 is a novel NO-donating prostaglandin analog in late-stage clinical development for the lowering of intraocular… |
